Trials / Completed
CompletedNCT05103241
A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers
Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 40 mg/100 μCi [14C]GP681 in Healthy Chinese Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]GP681 in healthy Chinese male volunteers, revealing the overall pharmacokinetic characteristics of GP681 in humans, and providing a reference for the rational administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C] GP681 | 40 mg suspension containing 100μCi of \[14C\]GP681 |
Timeline
- Start date
- 2021-10-26
- Primary completion
- 2021-11-22
- Completion
- 2021-11-22
- First posted
- 2021-11-02
- Last updated
- 2021-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05103241. Inclusion in this directory is not an endorsement.